On November 1, 2022 Chimeric Therapeutics (ASX: CHM, "Chimeric"), a clinical-stage cell therapy company and an Australian leader in cell therapy, reported that it has entered into a sponsored research agreement (SRA) with Case Western Reserve University (CWRU) to further advance Chimeric’s NK cell therapy portfolio (Press release, Chimeric Therapeutics, NOV 1, 2022, View Source [SID1234622760]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The research program at CWRU will be led by Dr David Wald, inventor of the CORE NK technology. Through this research collaboration, Dr Wald and his laboratory will work closely with Chimeric to advance multiple next-generation NK cell products through preclinical development, including CHM 0301 (Next-Generation CORE-NK Platform), CHM 1301 (Chlorotoxin CAR NK), CHM 2301 (CDH17 CAR NK), and CHM 3301 (undisclosed CAR NK).
Chimeric’s NK cell therapy portfolio foundational asset, CHM 0201 (CORE NK platform) was invented and developed by Dr Wald at Case Western. CHM 0201 was studied in a phase 1 clinical trial at Seidman Cancer Center in Ohio with promising outcomes that were published1 earlier this year. All key endpoints of the study were achieved, including safety with no graft versus host disease, cell persistence and cell expansion. In addition, an encouraging efficacy signal was demonstrated, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained through to 15 months at time of study publication.
"With the encouraging clinical data seen with CHM 0201 (CORE NK cell platform) we are very excited to be enhancing our collaboration with Dr Wald and his team at Case Western. By building upon Dr Wald’s NK cell scientific experience and expertise we believe we will be able to advance NK cell therapies to benefit patients in multiple disease areas in the future" said Jennifer Chow, CEO and Managing Director Chimeric Therapeutics.
Dr Wald is an Associate Professor, Department of Pathology, School of Medicine, CWRU, a member of the Immune Oncology Program, Case Comprehensive Cancer Center, and the Associate Director for Basic Research, University Hospitals, Wesley Center for Immunotherapy.
Under the SRA, Chimeric receives the exclusive option to license intellectual property created For personal use only by CWRU as part of the sponsored research. The agreement is outcomes based on research aims for an initial period estimated to be two years, which may be extended by mutual agreement of the parties.
Investor webinar
Chimeric Therapeutics CEO and Managing Director Jennifer Chow, CMO Dr Jason B Litten and Dr David Wald will hold an investor webinar tomorrow, Thursday 3 November 2022 at 9am AEDT to elaborate on this announcement and take questions.
Click the link below to register: View Source
After registering, you will receive a confirmation email about how to join the webinar. A recording of the webinar will be available at the same link shortly after the conclusion of the session.
¹ ASX announcement, 7 March 2022